DataLibraryResearch is tracking the market dynamics of the crisis in the Pharma & Healthcare industry amid lock-down changes in the supply chain.

Get detailed analysis of the COVID-19 impact on the Cancer Gene Therapy Market

Global Cancer Gene Therapy Market Opportunities and Forecast 2020-2027

  • DLR2470
  • 30 July, 2021
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global Cancer Gene Therapy Market, By Therapy (Gene Induced Immunotherapy, [Delivery of Cytokines Gene, Delivery of Tumor Antigen Gene], Oncolytic Virotherapy [Adenovirus, Lentivirus, Retro Virus, Adeno Associated Virus, Herpes Simplex Virus, Alpha Virus, Vaccinia Virus, Simian Virus, Others], Gene Transfer [Naked/Plasmid Vectors, Electroporation, Sonoportion, Magnetofection, Gene Gun], By End User (Hospitals, Diagnostics Centers, Research Institutes), and opportunities and forecast 2020-2027

Cancer Gene Therapy Market Overview

Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer. The increasing prevalence of cancer is one of the key reasons that boost the growth of the global Cancer Gene Therapy market. According to National Cancer Institute, Cancer is among the leading causes of death worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million.

Currently, CAR T-cell use has gathered significant attention from the sponsors following the exhibition of its huge potential in the treatment of several diseases. The promising future of CAR T-cell is projected to intensify the growth opportunities of the global gene therapy market. Furthermore, noteworthy progress has been made in the fields of cellular and molecular biology is expected to enlarge the growth of the global gene therapy market in the coming years. Moreover, rapid technological development made in the gene-editing and genomics tools is further projected to hike the demand for gene therapy. Eventually it fuel the growth of the market.

However, the high treatment cost is a major barrier to the growth of the cancer gene therapy market. Additionally, rising government funding and initiatives, growth in the pipeline of cancer gene therapy products, and collaborations to develop and launch gene-therapy products are some other important factors remarkably propelling the growth of the Cancer Gene Therapy market.

Covid-19 Impact on Cancer Gene Therapy Market:

In addition, the current Cancer Gene Therapy Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Cancer Gene Therapy Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.

The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.

Cancer Gene Therapy Market Segment Overview

Based on therapy, the Gene Transfer segment has significant growth in the global Cancer Gene Therapy market. Gene transfer is a new treatment modality that introduces new genes into a cancerous cell or the surrounding tissue to cause cell death or slow the growth of cancer. This treatment technique is very flexible, and a wide range of genes and vectors are being used in clinical trials with successful outcomes. As these therapies mature, they may be used alone or in combination with current treatments to help make cancer a manageable disease.

Cancer Gene Therapy Market, By Therapy
  • Gene Induced Immunotherapy
    • Delivery of Cytokines Gene
    • Delivery of Tumor Antigen Gene
  • Oncolytic Virotherapy
    • Adenovirus
    • Lentivirus
    • Retro Virus
    • Adeno Associated Virus
    • Herpes Simplex Virus
    • Alpha Virus
    • Vaccinia Virus
    • Simian Virus
    • Others
  • Gene Transfer
    • Naked/Plasmid Vectors
    • Electroporation
    • Sonoportion
    • Magnetofection
    • Gene Gun
Cancer Gene Therapy Market, By End User

·       Hospitals
·       Diagnostics Centers
·       Research Institutes

Cancer Gene Therapy Market Regional Overview

In terms of region, North America is projected to hold the largest share of the global Cancer Gene Therapy market. The U.S. is the prominent market for cancer gene therapy due to its increased funding for research & development and other government initiatives. Moreover, other factors such as the rising demand for DNA vaccines and the increasing interest of venture capitalists to invest in the commercialization of gene-based cancer therapies are expected to boost the market in this region. Similarly, the market in Asia-Pacific is expected to witness significant growth during the forecast period. China's cancer gene therapy is estimated to attribute for largest revenue, due to the recent launch of Gendicine and growing healthcare expenditure. This prime factor contributes significantly to the market’s expansion in this region. 

Cancer Gene Therapy Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)

Cancer Gene Therapy Market Competitor overview

Some key developments and strategies adopted by manufacturers in Cancer Gene Therapy are highlighted below.

·       In July 2021, OncoSec Medical Inc. will evaluate its DNA-plasmid interleukin-12 (IL-12) TAVO (tavokinogene telseplasmid) with Merck & Co Inc's Keytruda (pembrolizumab) in KEYNOTE-C87 Phase 3 trial. The planned trial will evaluate the overall survival of patients treated with the TAVO / Keytruda combination versus standard of care in late-stage patients with metastatic melanoma who are refractory to immune checkpoint therapy.

Cancer Gene Therapy Market, Key Players

·       Adaptimmune
·       ZioPharm Oncology Altor Bioscience
·       MolMed
·       bluebird bio
·       Shanghai Sunway Biotech company limited
·       MultiVir
·       Shenzhen SiBiono GeneTech, Corporation
·       GlaxoSmithKline
·       Merck
·       Celgene
·       BioCancell
·       SynerGene Therapeutics
·       OncoGenex Pharmaceuticals

Cancer Gene Therapy Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Cancer Gene Therapy Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Therapy
        • 5.2.1. Gene Induced Immunotherapy
          • 5.2.1.1. Delivery of Cytokines Gene
          • 5.2.1.2. Delivery of Tumor Antigen Gene
        • 5.2.2. Oncolytic Virotherapy
          • 5.2.2.1. Adenovirus
          • 5.2.2.2. Lentivirus
          • 5.2.2.3. Retro Virus
          • 5.2.2.4. Adeno Associated Virus
          • 5.2.2.5. Herpes Simplex Virus
          • 5.2.2.6. Alpha Virus
          • 5.2.2.7. Vaccinia Virus
          • 5.2.2.8. Simian Virus
          • 5.2.2.9. Others
        • 5.2.3. Gene Transfer
          • 5.2.3.1. Naked/Plasmid Vectors
          • 5.2.3.2. Electroporation
          • 5.2.3.3. Sonoportion
          • 5.2.3.4. Magnetofection
          • 5.2.3.5. Gene Gun
    • 5.3. Market Analysis, Insights and Forecast – By End User
      • 5.3.1. Hospitals
      • 5.3.2. Diagnostics Centers
      • 5.3.3. Research Institutes
    • 5.4. Market Analysis, Insights and Forecast – By Region
      • 5.4.1. North America
      • 5.4.2. Europe
      • 5.4.3. Asia Pacific
      • 5.4.4. Latin America, Middle East and Africa
    • 6. North America Cancer Gene Therapy Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Therapy
        • 6.2.1. Gene Induced Immunotherapy
          • 6.2.1.1. Delivery of Cytokines Gene
          • 6.2.1.2. Delivery of Tumor Antigen Gene
        • 6.2.2. Oncolytic Virotherapy
          • 6.2.2.1. Adenovirus
          • 6.2.2.2. Lentivirus
          • 6.2.2.3. Retro Virus
          • 6.2.2.4. Adeno Associated Virus
          • 6.2.2.5. Herpes Simplex Virus
          • 6.2.2.6. Alpha Virus
          • 6.2.2.7. Vaccinia Virus
          • 6.2.2.8. Simian Virus
          • 6.2.2.9. Others
        • 6.2.3. Gene Transfer
          • 6.2.3.1. Naked/Plasmid Vectors
          • 6.2.3.2. Electroporation
          • 6.2.3.3. Sonoportion
          • 6.2.3.4. Magnetofection
          • 6.2.3.5. Gene Gun
    • 6.3. Market Analysis, Insights and Forecast – By End User
      • 6.3.1. Hospitals
      • 6.3.2. Diagnostics Centers
      • 6.3.3. Research Institutes
    • 6.4. Market Analysis, Insights and Forecast – By Country
      • 6.4.1. U.S.
      • 6.4.2. Canada
    • 7. Europe Cancer Gene Therapy Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Therapy
        • 7.2.1. Gene Induced Immunotherapy
          • 7.2.1.1. Delivery of Cytokines Gene
          • 7.2.1.2. Delivery of Tumor Antigen Gene
        • 7.2.2. Oncolytic Virotherapy
          • 7.2.2.1. Adenovirus
          • 7.2.2.2. Lentivirus
          • 7.2.2.3. Retro Virus
          • 7.2.2.4. Adeno Associated Virus
          • 7.2.2.5. Herpes Simplex Virus
          • 7.2.2.6. Alpha Virus
          • 7.2.2.7. Vaccinia Virus
          • 7.2.2.8. Simian Virus
          • 7.2.2.9. Others
        • 7.2.3. Gene Transfer
          • 7.2.3.1. Naked/Plasmid Vectors
          • 7.2.3.2. Electroporation
          • 7.2.3.3. Sonoportion
          • 7.2.3.4. Magnetofection
          • 7.2.3.5. Gene Gun
    • 7.3. Market Analysis, Insights and Forecast – By End User
      • 7.3.1. Hospitals
      • 7.3.2. Diagnostics Centers
      • 7.3.3. Research Institutes
    • 7.4. Market Analysis, Insights and Forecast – By Country
      • 7.4.1. UK
      • 7.4.2. Germany
      • 7.4.3. France
      • 7.4.4. Italy
      • 7.4.5. Spain
      • 7.4.6. Russia
      • 7.4.7. Rest of Europe
    • 8. Asia Pacific Cancer Gene Therapy Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Therapy
        • 8.2.1. Gene Induced Immunotherapy
          • 8.2.1.1. Delivery of Cytokines Gene
          • 8.2.1.2. Delivery of Tumor Antigen Gene
        • 8.2.2. Oncolytic Virotherapy
          • 8.2.2.1. Adenovirus
          • 8.2.2.2. Lentivirus
          • 8.2.2.3. Retro Virus
          • 8.2.2.4. Adeno Associated Virus
          • 8.2.2.5. Herpes Simplex Virus
          • 8.2.2.6. Alpha Virus
          • 8.2.2.7. Vaccinia Virus
          • 8.2.2.8. Simian Virus
          • 8.2.2.9. Others
        • 8.2.3. Gene Transfer
          • 8.2.3.1. Naked/Plasmid Vectors
          • 8.2.3.2. Electroporation
          • 8.2.3.3. Sonoportion
          • 8.2.3.4. Magnetofection
          • 8.2.3.5. Gene Gun
    • 8.3. Market Analysis, Insights and Forecast – By End User
      • 8.3.1. Hospitals
      • 8.3.2. Diagnostics Centers
      • 8.3.3. Research Institutes
    • 8.4. Market Analysis, Insights and Forecast – By Country
      • 8.4.1. China
      • 8.4.2. India
      • 8.4.3. Japan
      • 8.4.4. Australia
      • 8.4.5. South East Asia
      • 8.4.6. Rest of Asia Pacific
    • 9. Latin America, Middle East and Africa Cancer Gene Therapy Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 9.1. Key Findings / Summary
      • 9.2. Market Analysis, Insights and Forecast – By Therapy
        • 9.2.1. Gene Induced Immunotherapy
          • 9.2.1.1. Delivery of Cytokines Gene
          • 9.2.1.2. Delivery of Tumor Antigen Gene
        • 9.2.2. Oncolytic Virotherapy
          • 9.2.2.1. Adenovirus
          • 9.2.2.2. Lentivirus
          • 9.2.2.3. Retro Virus
          • 9.2.2.4. Adeno Associated Virus
          • 9.2.2.5. Herpes Simplex Virus
          • 9.2.2.6. Alpha Virus
          • 9.2.2.7. Vaccinia Virus
          • 9.2.2.8. Simian Virus
          • 9.2.2.9. Others
        • 9.2.3. Gene Transfer
          • 9.2.3.1. Naked/Plasmid Vectors
          • 9.2.3.2. Electroporation
          • 9.2.3.3. Sonoportion
          • 9.2.3.4. Magnetofection
          • 9.2.3.5. Gene Gun
    • 9.3. Market Analysis, Insights and Forecast – By End User
      • 9.3.1. Hospitals
      • 9.3.2. Diagnostics Centers
      • 9.3.3. Research Institutes
    • 9.4. Market Analysis, Insights and Forecast – By Country
      • 9.4.1. Brazil
      • 9.4.2. Saudi Arabia
      • 9.4.3. UAE
      • 9.4.4. Rest of LAMEA
    • 10. Competitive Analysis

      • 10.1. Company Market Share Analysis, 2018
      • 10.2. Key Industry Developments
      • 10.3. Company Profile
      • 10.4. Adaptimmune
        • 10.4.1. Business Overview
        • 10.4.2. Segment 1 & Service Offering
        • 10.4.3. Overall Revenue
        • 10.4.4. Geographic Presence
        • 10.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 10.5. ZioPharm Oncology Altor Bioscience
      • 10.6. MolMed
      • 10.7. bluebird bio
      • 10.8. Shanghai Sunway Biotech company limited
      • 10.9. MultiVir
      • 10.10. Shenzhen SiBiono GeneTech, Corporation
      • 10.11. GlaxoSmithKline
      • 10.12. Merck
      • 10.13. Celgene
      • 10.14. BioCancell
      • 10.15. SynerGene Therapeutics
      List of Figures

      Figure 1: Global Cancer Gene Therapy Market Revenue Breakdown (USD Billion, %) by Region, 2019 & 2027
      Figure 2: Global Cancer Gene Therapy Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 3: Global Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 4: Global Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 5: Global Cancer Gene Therapy Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 6: Global Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 7: Global Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 8: Global Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 9: Global Cancer Gene Therapy Market Forecast (USD Billion), by Others, 2016-2027
      Figure 10: Global Cancer Gene Therapy Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 11: Global Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 12: Global Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 13: Global Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 14: Global Cancer Gene Therapy Market Forecast (USD Billion), by Others, 2016-2027
      Figure 15: Global Cancer Gene Therapy Market Value (USD Billion), by Region, 2019 & 2027
      Figure 16: North America Cancer Gene Therapy Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 17: North America Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 18: North America Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 19: North America Cancer Gene Therapy Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 20: North America Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 21: North America Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 22: North America Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 23: North America Cancer Gene Therapy Market Forecast (USD Billion), by Others, 2016-2027
      Figure 24: North America Cancer Gene Therapy Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 25: North America Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 26: North America Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 27: North America Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 28: North America Cancer Gene Therapy Market Forecast (USD Billion), by Others, 2016-2027
      Figure 29: North America Cancer Gene Therapy Market Forecast (USD Billion), by U.S., 2016-2027
      Figure 30: North America Cancer Gene Therapy Market Forecast (USD Billion), by Canada, 2016-2027
      Figure 31: Latin America Cancer Gene Therapy Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 32: Latin America Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 33: Latin America Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 34: Latin America Cancer Gene Therapy Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 35: Latin America Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 36: Latin America Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 37: Latin America Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 38: Latin America Cancer Gene Therapy Market Forecast (USD Billion), by Others, 2016-2027
      Figure 39: Latin America Cancer Gene Therapy Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 40: Latin America Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 41: Latin America Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 42: Latin America Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 43: Latin America Cancer Gene Therapy Market Forecast (USD Billion), by Others, 2016-2027
      Figure 44: Latin America Cancer Gene Therapy Market Forecast (USD Billion), by Brazil, 2016-2027
      Figure 45: Latin America Cancer Gene Therapy Market Forecast (USD Billion), by Mexico, 2016-2027
      Figure 46: Latin America Cancer Gene Therapy Market Forecast (USD Billion), by Rest of Latin America, 2016-2027
      Figure 47: Europe Cancer Gene Therapy Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 48: Europe Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 49: Europe Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 50: Europe Cancer Gene Therapy Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 51: Europe Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 52: Europe Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 53: Europe Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 54: Europe Cancer Gene Therapy Market Forecast (USD Billion), by Others, 2016-2027
      Figure 55: Europe Cancer Gene Therapy Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 56: Europe Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 57: Europe Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 58: Europe Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 59: Europe Cancer Gene Therapy Market Forecast (USD Billion), by Others, 2016-2027
      Figure 60: Europe Cancer Gene Therapy Market Forecast (USD Billion), by U.K., 2016-2027
      Figure 61: Europe Cancer Gene Therapy Market Forecast (USD Billion), by Germany, 2016-2027
      Figure 62: Europe Cancer Gene Therapy Market Forecast (USD Billion), by France, 2016-2027
      Figure 63: Europe Cancer Gene Therapy Market Forecast (USD Billion), by Italy, 2016-2027
      Figure 64: Europe Cancer Gene Therapy Market Forecast (USD Billion), by Spain, 2016-2027
      Figure 65: Europe Cancer Gene Therapy Market Forecast (USD Billion), by Russia, 2016-2027
      Figure 66: Europe Cancer Gene Therapy Market Forecast (USD Billion), by Rest of Europe, 2016-2027
      Figure 67: Asia Pacific Cancer Gene Therapy Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 68: Asia Pacific Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 69: Asia Pacific Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 70: Asia Pacific Cancer Gene Therapy Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 71: Asia Pacific Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 72: Asia Pacific Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 73: Asia Pacific Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 74: Asia Pacific Cancer Gene Therapy Market Forecast (USD Billion), by Others, 2016-2027
      Figure 75: Asia Pacific Cancer Gene Therapy Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 76: Asia Pacific Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 77: Asia Pacific Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 78: Asia Pacific Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 79: Asia Pacific Cancer Gene Therapy Market Forecast (USD Billion), by Others, 2016-2027
      Figure 80: Asia Pacific Cancer Gene Therapy Market Forecast (USD Billion), by China, 2016-2027
      Figure 81: Asia Pacific Cancer Gene Therapy Market Forecast (USD Billion), by India, 2016-2027
      Figure 82: Asia Pacific Cancer Gene Therapy Market Forecast (USD Billion), by Japan, 2016-2027
      Figure 83: Asia Pacific Cancer Gene Therapy Market Forecast (USD Billion), by Australia, 2016-2027
      Figure 84: Asia Pacific Cancer Gene Therapy Market Forecast (USD Billion), by Southeast Asia, 2016-2027
      Figure 85: Asia Pacific Cancer Gene Therapy Market Forecast (USD Billion), by Rest of Asia Pacific, 2016-2027
      Figure 86: Middle East & Africa Cancer Gene Therapy Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 87: Middle East & Africa Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 88: Middle East & Africa Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 89: Middle East & Africa Cancer Gene Therapy Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 90: Middle East & Africa Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 91: Middle East & Africa Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 92: Middle East & Africa Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 93: Middle East & Africa Cancer Gene Therapy Market Forecast (USD Billion), by Others, 2016-2027
      Figure 94: Middle East & Africa Cancer Gene Therapy Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 95: Middle East & Africa Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 96: Middle East & Africa Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 97: Middle East & Africa Cancer Gene Therapy Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 98: Middle East & Africa Cancer Gene Therapy Market Forecast (USD Billion), by Others, 2016-2027
      Figure 99: Middle East & Africa Cancer Gene Therapy Market Forecast (USD Billion), by GCC, 2016-2027
      Figure 100: Middle East & Africa Cancer Gene Therapy Market Forecast (USD Billion), by South Africa, 2016-2027
      Figure 101: Middle East & Africa Cancer Gene Therapy Market Forecast (USD Billion), by Rest of Middle East & Africa, 2016-2027 
      List of Tables
      Table 1: Global Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 2: Global Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 3: Global Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 4: Global Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Region, 2016-2027
      Table 5: North America Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 6: North America Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 7: North America Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 8: North America Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 9: Europe Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 10: Europe Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 11: Europe Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 12: Europe Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 13: Latin America Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 14: Latin America Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 15: Latin America Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 16: Latin America Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 17: Asia Pacific Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 18: Asia Pacific Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 19: Asia Pacific Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 20: Asia Pacific Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 21: Middle East & Africa Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 22: Middle East & Africa Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 23: Middle East & Africa Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 24: Middle East & Africa Cancer Gene Therapy Market Revenue (USD Billion) Forecast, by Country, 2016-2027

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      info@datalibraryresearch.com

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934